Frédéric Rochat is the president of the EuroVacc Foundation. Since 2008 he is partner with the law firm Kellerhals Carrard, with experience in the field of business and commercial law. Frédéric Rochat is board member and chairman of several Swiss companies and foundations.
Frédéric Rochat is a Swiss attorney-at-law, Dr of law, and a partner in the Lausanne office of the law firm Kellerhals Carrard. Frédéric was admitted to the bar of canton of Vaud in 2002, then of New York in 2005 and worked for several years in a US law firm in New York and London before returning to Lausanne in 2007, where he specializes in corporate, financial and contract law, with a particular focus on start-up and biotech companies.
Frédéric serves as member or chairman of the board of several Swiss companies and foundations. He also teaches law at various institutions such as EPFL (Legal Strategy in the executive MBA program), EXPERTsuisse (Swiss Company Law) and Venturelab (program for young entrepreneurs).
Through his involvement and membership in various institutions, such as Health Sciences e-Training Foundation (board member), Gene Predictis SA (board member) or Vaud Biomed (member), as well as regular advice to his clients in the biotech sector, Frédéric has gained valuable legal expertise in this field.
| Protocol. Nr. | Description | Sponsor(s) | Trials Sites | Status | Results |
| PV1 (PrEPVac) | A Phase IIb three-arm, two-stage HIV prophylactic vaccine trial with a second randomisation to compare TAF/FTC to TDF/FTC as pre-exposure prophylaxis (PrEPVacc) | Imperial College London | Uganda, Tanzania, South Africa, Mozambique |
Started NCT04066881 |
Ongoing |
| HVTN111 | A phase 1 clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA and of MF59-adjuvanted clade C Env protein, in healthy, HIVuninfected adult participants |
DAIDS, NIH | South Africa, Tanzania, Zambia |
Completed NCT02997969 |
Hosseinipour 2020 |
| HVTN108 | A phase 1/2a clinical trial to evaluate the safety and immunogenicity of HIV clade C DNA, and of MF59®- or AS01B-adjuvanted clade C Env protein in various combinations, in healthy, HIV-uninfected adult participants | DAIDS, NIH | US, South Africa |
Completed NCT02915016 |
Manuscript in preparation |
| HVTN105 | A phase 1b clinical trial to evaluate the safety and immunogenicity of different combinations of DNA-HIV-PT123 and AIDSVAX® B/E in healthy, HIV uninfected adult participants | DAIDS, NIH | US | Completed NCT02207920 |
Rouphael 2019 |
| EV07 | An open label phase I clinical trial to evaluate the effect of late boost on HIV-uninfected vaccinees from EV06 trial | EVF | Uganda | Completed NCT03391375 |
Manuscript in preparation |
| EV06 | A phase I double blind placebo-controlled clinical trial to evaluate the safety and immunogenicity of the combination of DNA-HIV-PT123 and AIDSVAX®B/E in HIV-1-uninfected adult participants with or without underlying Schistosoma mansoni infection | EVF | Uganda | Completed NCT02516306 |
Manuscript in preparation |
| HVTN096/ EV04 | A phase I double blind placebo-controlled clinical trial to evaluate the safety and to compare the priming ability of NYVAC alone versus NYVAC + AIDSVAX® B/E, and DNA alone versus DNA + AIDSVAX® B/E when followed by NYVAC + AIDSVAX® B/E boosts in healthy, HIV-1-uninfected adult participants | DAIDS/ EVF | Switzerland | Completed NCT01799954 |
Pantaleo 2019 |
| HVTN092 | A phase I clinical trial to evaluate safety and to compare the immunogenicity of 3 DNA vaccine Prime schedules followed by a NYVAC vaccine boost in healthy, HIV-1 uninfected adult participants | DAIDS | Switzerland, US | Discontinued NCT01783977 |
|
| HVTN078 | A phase Ib clinical trial to evaluate the safety and immunogenicity of heterologous prime/boost vaccine regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in healthy, HIV-1 uninfected, Ad5 seronegative adult participants | DAIDS / EVF | Switzerland | Completed NCT00961883 |
Bart 2014 |
| EV03/
ANRSVAC20 |
Phase II Immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost versus 2 DNA-C prime followed by 2 NYVAC-C boost |
EVF/ ANRS |
Switzerland, UK, Germany, France | Completed NCT00490074 |
Levy 2020 |
| EV02 | Phase I Safety and Immunogenicity comparing DNA-C prime and NYVAC-C boost versus NYVAC-C alone |
EVF | Switzerland, UK | Completed | Harari 2008 |
| EV01 | Phase I Safety and Immunogenicity Study of NYVAC-C alone |
Imperial College London | Switzerland, UK | Completed |
| Protocol. Nr. | Description | Sponsor(s) | Trials Sites | Status | Results |
| TheraVac01 | Phase I NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected ART-treated HIV patients |
EVF | Switzerland | Completed | Harari 2012 |
| TheraVac02 | Phase I safety of MVA-B in chronic HIV-1 infected patients successfully treated with HAART |
EVF | The Netherlands | Completed | Vermeulen 2008 Abstract |
Jonathan Heeney is Professor of Comparative Pathology at the University of Cambridge. His work bridges both Veterinary and Human medicine, infectious diseases and oncology. He has over 20 years of experience working with both academia and industry to navigate vaccine candidates through preclinical development to clinical trial. He has a long established track record of management of large international consortia.
His new laboratory in Cambridge studies cross-species transmissions of viral diseases and the mechanisms of immunity in new and established hosts. His multi-discipline research team has developed new technologies for the detection and monitoring of viruses, and the characterization of new and novel pathogens.
Jonathan Heeney has made a number of key contributions to AIDS vaccine development including defining the central role of T-helper responses in vaccine induced immunity, in demonstrating viral vaccine protection from cell-associated challenge and the role of chemokine responses in protective immunity.
He has a comparative approach to vaccine development with the establishment of clinically definable endpoints early in the preclinical evaluation process. Jonathan Heeney pioneered the use of immune correlates in rational vaccine development and is the founder of an international series of meetings on correlates of protective immunity to HIV/AIDS.
Mariano Esteban is professor of Spanish CSIC and former Director of the National Centre of Biotechnology (1992-2003). He returned to Spain in 1992 after 22 years abroad, mostly in the USA, where he was professor of Biochemistry and Microbiology at the Downstate Medical Center in Brooklyn, State University of New York (SUNY), NY.
Mariano Esteban is an internationally-recognized scientist with a long experience in molecular basis of pathogenesis by infectious agents. In particular, his group has made important contributions in understanding the lifecycle of vaccinia virus and the mechanism of action of interferons. Mariano Esteban used this knowledge to develop vaccinia-vectors that are candidates against prevalent human diseases caused by viruses (HIV, hepatitis C, influenza, chikungunya), parasitic (malaria and leishmania) and cancer. His group pioneered a prime/boost approach that gained acceptance as an immunization protocol against different diseases, and has made significant contributions in the biology and application of the attenuated poxvirus vectors MVA and NYVAC as vaccine candidates. Some of these vaccines have entered phase I/II clinical trials, like HIV.
Prof. Esteban is a Member of prestigious Academies and societies and currently holds the Presidency of the Royal Academy of Pharmacy in Spain. He has published more than 300 articles in peer review international journals.
Peter Liljeström holds since 1996 a full professorship at the Department of Microbiology, Tumor and Cell Biology at the Karolinska Institutet in Stockholm, Sweden. During 1996-2010 he was also head of the Department of Vaccines at the Swedish Institute for Communicable Disease Control overseeing the immunization programme of Sweden.
Peter Liljeström is an internationally recognized scientist and has made significant contributions in the fields of vaccine development, molecular virology and virus host interactions. He is the developer of the RNA replicon vector platform, which is widely used both as expression system and is now strongly applied as a basis for recombinant vaccines against infectious disease and cancer.
During the past 20 years Peter Liljeström has been involved in evaluation of different vaccination modalities and studies of mechanisms underlying immune correlates of protection. He has coordinated five EU research networks and has been a member of the WHO Steering committees for Flavivirus Vaccines and New Vaccines.
Giuseppe Pantaleo is Professor of medicine and Chief of the Division of Immunology and Allergy at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. He is also the Executive Director of the Swiss Vaccine Research Institute (SVRI).
Professor Pantaleo has made seminal contributions in the field of the immunopathogenesis of HIV infection. He has shown that HIV disease is active and progressive during the period of clinical latency. Furthermore, he has also made substantial contributions to the characterization of virus specific T-cell responses.
Since 1998 he has been leading a European program in the development of an HIV vaccine platform. Since 1998, he has been one of the major contributors to the development of a HIV research vaccine project using poxviruses as platform.
Professor Pantaleo is currently leading several international programs supported by the Bill and Melinda Gates Foundation and the European Commission.
Jean-Philippe Rochat is the former president since the inception of the EuroVacc Foundation until 2017. Since 1990 he is partner with the law firm Kellerhals Carrard, with experience in the field of business and commercial law.
Jean-Philippe Rochat is a member of the Board of directors and chairman of several Swiss corporations in the field of industry, finance and trading. He is member of the Board of several foundations.
